<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pharm Health Care Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Pharm Health Care Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2871</journal-id><journal-id journal-id-type="pmc-domain">jphcs</journal-id><journal-title-group><journal-title>Journal of Pharmaceutical Health Care and Sciences</journal-title></journal-title-group><issn pub-type="epub">2055-0294</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9987070</article-id><article-id pub-id-type="pmcid-ver">PMC9987070.1</article-id><article-id pub-id-type="pmcaid">9987070</article-id><article-id pub-id-type="pmcaiid">9987070</article-id><article-id pub-id-type="pmid">36872399</article-id><article-id pub-id-type="doi">10.1186/s40780-023-00278-x</article-id><article-id pub-id-type="publisher-id">278</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of polypharmacy on plasma bepridil concentration in patients with heart failure: a multicenter retrospective study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1933-8592</contrib-id><name name-style="western"><surname>Asai</surname><given-names initials="Y">Yuki</given-names></name><address><email>yuki0715asai@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arihara</surname><given-names initials="H">Hiroki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Omote</surname><given-names initials="S">Saki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tanio</surname><given-names initials="E">Ena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamashita</surname><given-names initials="S">Saena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Higuchi</surname><given-names initials="T">Takashi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names initials="E">Ei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamada</surname><given-names initials="M">Momoko</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsuji</surname><given-names initials="H">Hinako</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kondo</surname><given-names initials="Y">Yoshihiro</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hayashi</surname><given-names initials="M">Makoto</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names initials="Y">Yoshiaki</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.505758.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 7286</institution-id><institution>Pharmacy, National Hospital Organization Mie Chuo Medical Center, </institution></institution-wrap>2158-5 Hisaimyojin, Tsu, Mie 514-1101 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.414958.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0569 1891</institution-id><institution>Pharmacy, National Hospital Organization Kanazawa Medical Center, </institution></institution-wrap>1-1, Shimoishibiki, Kanazawa, Ishikawa 920-0850 Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.410840.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 7902</institution-id><institution>Pharmacy, National Hospital Organization Nagoya Medical Center, </institution></institution-wrap>4-1-1, Sannomaru, Naka-ku, Nagoya, 460-0001 Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.419174.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0618 9684</institution-id><institution>Department of Clinical Research, </institution><institution>National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders, </institution></institution-wrap>886 Urushiyama, Shizuoka, 420-8688 Japan </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">425962</issue-id><elocation-id>10</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>07</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-07 04:10:14.213"><day>07</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40780_2023_Article_278.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Polypharmacy, defined as the concurrent use of over six drugs, is common in the treatment of heart failure (HF); however, unpredictable drug interactions with bepridil may occur. In this study, we have elucidated the influence of polypharmacy on plasma bepridil concentrations in patients with HF.</p></sec><sec><title>Methods</title><p id="Par2">We conducted a multicenter retrospective study involving 359 adult patients with HF who received oral bepridil. Because QT prolongation is an adverse effect following plasma bepridil concentrations &#8805;800&#8201;ng/mL, the risk factors for patients achieving these concentrations at steady state were elucidated via multivariate logistic regression. The correlation between bepridil dose and plasma concentration was examined. The effect of polypharmacy on the value of the concentration-to-dose (C/D) ratio was investigated.</p></sec><sec><title>Results</title><p id="Par3">A significant relationship was observed between bepridil dose and plasma concentration (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;&#160;0.001), and the intensity of the correlation was moderate (<italic toggle="yes">r</italic>&#8201;=&#8201;0.503). Based on multivariate logistic regression, the adjusted odds ratios for a daily dose of bepridil &#8805;1.6&#8201;mg/kg, polypharmacy, and concomitant of aprindine, a cytochrome P450 2D6 inhibitor, were 6.82 (95% coefficient interval: 2.104&#8211;22.132, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001), 2.96 (95% coefficient interval: 1.014&#8211;8.643, <italic toggle="yes">p</italic>&#8201;=&#8201;0.047), and 8.63 (95% coefficient interval: 1.684&#8211;44.215, <italic toggle="yes">p</italic>&#8201;=&#8201;0.010), respectively. Despite the moderate correlation in non-polypharmacy, the correlation was not observed in polypharmacy. Therefore, inhibiting metabolism, along with other mechanisms, may contribute to the polypharmacy-induced increase in plasma bepridil concentrations. Moreover, the C/D ratios in the groups receiving 6&#8211;9 and&#8201;10&#8804; concomitant drugs were 1.28- and 1.70-fold higher than in those receiving &lt;6 drugs, respectively.</p></sec><sec><title>Conclusions</title><p id="Par4">Plasma bepridil concentrations may be influenced by polypharmacy. Moreover, the plasma bepridil concentration increased in correlation with the number of concomitant drugs used. Although the mechanism of this increase could not be determined, plasma bepridil concentrations should be periodically monitored for safe use in patients with HF.</p></sec><sec><title>Trial registration</title><p id="Par5">Retrospectively registered.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bepridil</kwd><kwd>Heart failure</kwd><kwd>Polypharmacy</kwd><kwd>Drug-drug interaction</kwd><kwd>Therapeutic drug monitoring</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>22K15331</award-id><principal-award-recipient><name name-style="western"><surname>Asai</surname><given-names>Yuki</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par6">Bepridil has various channel-blocking properties and has been widely used as an antiarrhythmic drug [<xref ref-type="bibr" rid="CR1">1</xref>]. Recently, the use of bepridil administration has been considered a second-line therapy for patients with atrial fibrillation (AF) who are refractory to treatment with other antiarrhythmic drugs in Japan [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref>]. However, bepridil treatment often causes QT prolongation and torsades de pointes [<xref ref-type="bibr" rid="CR3">3</xref>]. Matsui et al. reported that the QTc interval is strongly associated with plasma bepridil concentration [<xref ref-type="bibr" rid="CR5">5</xref>], and it is associated with an increased risk when the plasma concentration of bepridil exceeds 800&#8201;ng/mL [<xref ref-type="bibr" rid="CR3">3</xref>], indicating that therapeutic drug monitoring of plasma bepridil concentration is essential for safety in clinical settings.</p><p id="Par7">Bepridil treatment is likely to cause inter-individual variability in plasma concentrations owing to its low bioavailability (&lt;&#8201;60%), large volume of distribution (8&#8201;L/kg), and long half-life (48&#8211;80&#8201;h) [<xref ref-type="bibr" rid="CR6">6</xref>]. In patients with heart failure (HF), the clearance of various antiarrhythmic drugs has been reported to decrease owing to a large change in blood flow in the systemic circulation [<xref ref-type="bibr" rid="CR7">7</xref>], suggesting that the dose adjustment of bepridil in patients with HF, who represent a unique population, is more important than that in patients without HF. However, the factors influencing the increase in plasma bepridil concentration in patients with HF remain unknown.</p><p id="Par8">As patients with HF have several comorbidities, drug therapy for HF currently involves polypharmacy [<xref ref-type="bibr" rid="CR8">8</xref>]. In Japan, polypharmacy is generally defined as the concomitant use of six or more drugs due to the increased risk of side effects in patients taking six and more than six drugs concomitantly [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Typically, polypharmacy increases the risk of potential and unpredictable drug&#8211;drug interactions associated with drug-metabolizing enzymes and efflux transporters, such as Cytochrome P450 (CYP) and P-glycoprotein (P-gp) [<xref ref-type="bibr" rid="CR11">11</xref>]. This phenomenon causes an increase or decrease in the blood concentrations of concomitant drugs. In addition, a previous study revealed that bepridil is mainly metabolized by hepatic CYP2D6 and partly by CYP3A [<xref ref-type="bibr" rid="CR12">12</xref>]. Moreover, bepridil is a substrate of P-gp [<xref ref-type="bibr" rid="CR13">13</xref>], suggesting that polypharmacy in HF may alter plasma bepridil concentrations; however, the details have not been elucidated. Therefore, a multicenter retrospective study was performed to clarify the effect of polypharmacy on plasma bepridil concentrations in patients with HF.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par9">This multicenter retrospective study was conducted at three hospitals belonging to the Tokai-Hokuriku Group of the National Hospital Organization (Kanazawa Medical Center, Mie Chuo Medical Center, and Nagoya Medical Center).</p></sec><sec id="Sec4"><title>Participants</title><p id="Par10">The data on patients receiving oral bepridil at the three hospitals from January 1, 2011, to December 31, 2021, were collected. In this study, patients with HF were defined as those diagnosed with HF by an attending physician based on a comprehensive evaluation of their symptoms and medical history. The inclusion criteria were defined as HF patients of age&#8201;&#8805;&#8201;18&#8201;years who were receiving oral bepridil. The following patients were excluded from the analysis as follows: (1) patients with no plasma bepridil measurement, (2) patients without echocardiography data, (3) patients undergoing hemodialysis, and (4) missing data. In this study, patients who had been administered bepridil for at least 28&#8201;days beyond the steady state were selected for analysis as previously reported [<xref ref-type="bibr" rid="CR14">14</xref>]. Blood samples were stored at 4&#8201;&#176;C until measurement. The measurement of their plasma bepridil concentrations via liquid chromatography-tandem mass spectrometry was outsourced to SRL, Inc. (Tokyo, Japan) or LSI Medience Corporation (Tokyo, Japan). In addition, patients with bepridil concentration below the limit of quantification (&lt;&#8201;20&#8201;ng/mL) were excluded. For patients who received therapeutic drug monitoring of bepridil twice or more during this study period, drug concentration data obtained from the last measurement were included in the analysis.</p></sec><sec id="Sec5"><title>Data collection and analysis</title><p id="Par11">The collection time of the plasma sample included data from before administration of bepridil to up to 6&#8201;h after administration. To assess risk factors for achieving plasma bepridil concentrations &#8805;800&#8201;ng/mL at steady state, the eligible patients were divided into two groups based on their bepridil concentrations: &#8805;800&#8201;ng/mL and&#8201;&lt;&#8201;800&#8201;ng/mL.</p><p id="Par12">The C/D ratio was calculated using the following equation:</p><p id="Par13">C/D ratio of bepridil&#8201;=&#8201;plasma concentration of bepridil (ng/mL) / dose of bepridil (mg/day/kg body weight).</p><p id="Par14">In this study, we defined the polypharmacy group as those who use six or more drugs, whereas the non-polypharmacy group was those who took fewer than six drugs. The relationship between plasma bepridil concentrations &#8805;800&#8201;ng/mL and baseline characteristics, including sex, age, height, body weight, body mass index, serum creatinine, creatinine clearance (Ccr), number of concomitant drugs used, typical inducers of CYPs (phenytoin, carbamazepine, phenobarbital, and rifampicin) [<xref ref-type="bibr" rid="CR15">15</xref>], typical inhibitors of CYPs (erythromycin, clarithromycin, protease inhibitors, and azole antifungals) [<xref ref-type="bibr" rid="CR15">15</xref>], aprindine, a competitive inhibitor of CYP2D6 [<xref ref-type="bibr" rid="CR12">12</xref>], typical inhibitor of P-gp (amiodarone, diltiazem, nicardipine, nifedipine, propranolol, quinidine, cyclosporin, and tacrolimus) [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>], and left ventricular ejection fraction (LVEF), were examined. LVEF was measured using echocardiographic equipment provided at each hospital. Ccr was estimated using the Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par15">The patient&#8217;s medical history and duration of bepridil treatment were collected from medical records.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par16">Correlations between bepridil dosage and its plasma concentration were analyzed using Spearman correlation coefficient analysis. Univariate analyses were performed as follows for continuous and categorical variables, respectively. Differences in continuous variables between the &#8805;800&#8201;ng/mL and&#8201;&lt;&#8201;800&#8201;ng/mL groups were analyzed using the Mann&#8211;Whitney U test as they followed a non-normal distribution. Categorical variables were compared using the chi-square test. Fisher&#8217;s exact test was selected to include one cell with an expected value of &lt;&#8201;5 on a 2&#8201;&#215;&#8201;2 contingency table. In the multivariate logistic regression analysis, the objective variable constituted plasma bepridil concentrations &#8805;800&#8201;ng/mL, whereas the explanatory variables included age, which reportedly influences plasma bepridil concentration [<xref ref-type="bibr" rid="CR20">20</xref>], and factors that showed <italic toggle="yes">p</italic>&#160;&lt;&#8201;&#160;0.05 in the univariate analysis. For enhanced clarity of clinical settings, when the continuous variables were included in the multivariate logistic regression model, the continuous variables were converted to categorical variables based on specified cut-off values. Specifically, the cut-off values for age and daily bepridil dose were the median values obtained considering all the eligible patients (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). For Ccr, the cutoff value was Ccr&#8201;&#8804;&#8201;30&#8201;mL/min, which signifies severe renal impairment, and for LVEF, it was LVEF &#8804;50%, which indicates a reduced LVEF. Furthermore, the Hosmer&#8211;Lemeshow test was used to assess the goodness of fit of the multivariate logistic regression model (<italic toggle="yes">p</italic>&#160;&gt;&#8201;0.05 was considered statistically significant). Multicollinearity was also evaluated using the variance inflation factor (VIF). To determine the number of concomitant drugs influencing the C/D ratio, the three groups were compared using the Kruskal&#8211;Wallis test, followed by Bonferroni correction for comparisons between groups. Statistical analyses were performed using SPSS Statistics version 27 (IBM Japan, Tokyo, Japan), and the significance level was set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;&#160;0.05.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Summary of patient data</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Factors</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;359</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sex (Male/Female)</td><td colspan="1" rowspan="1">238/121</td></tr><tr><td colspan="1" rowspan="1">Age (years)</td><td colspan="1" rowspan="1">71 (64, 79)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Height (m)</td><td colspan="1" rowspan="1">1.64 (1.55, 1.71)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Body weight (kg)</td><td colspan="1" rowspan="1">62.55 (54.68, 72.40)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1">23.41 (21.15, 25.65)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Serum creatinine (mg/dL)</td><td colspan="1" rowspan="1">0.88 (0.74, 1.03)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Ccr (mL/min)</td><td colspan="1" rowspan="1">64.63 (47.56, 86.03)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Daily dose of bepridil (mg/kg body weight)</td><td colspan="1" rowspan="1">1.58 (1.24, 2.02)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Period of bepridil treatment (day)</td><td colspan="1" rowspan="1">356 (124, 1404)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">Plasma bepridil concentration (ng/mL)</td><td colspan="1" rowspan="1">300 (157, 491)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">C/D ratio of bepridil (ng/mL) / (mg/day/kg)</td><td colspan="1" rowspan="1">186 (108, 278)</td></tr><tr><td colspan="1" rowspan="1">LVEF (%)</td><td colspan="1" rowspan="1">65.1 (59.1, 69.9)<sup>d</sup></td></tr><tr><td colspan="1" rowspan="1">&#8195;HFrEF<sup>a</sup>, n (%)</td><td colspan="1" rowspan="1">14 (3.9)</td></tr><tr><td colspan="1" rowspan="1">&#8195;HFmrEF<sup>b</sup>, n (%)</td><td colspan="1" rowspan="1">28 (7.8)</td></tr><tr><td colspan="1" rowspan="1">&#8195;HFpEF<sup>c</sup>, n (%)</td><td colspan="1" rowspan="1">317 (88.3)</td></tr><tr><td colspan="2" rowspan="1">Patient&#8217;s medical history, n (%)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Coronary artery bypass graft</td><td colspan="1" rowspan="1">3 (0.8)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Graft replacement</td><td colspan="1" rowspan="1">1 (0.3)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Atrial fibrillation</td><td colspan="1" rowspan="1">346 (94.3)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Heart valve replacement or formation</td><td colspan="1" rowspan="1">8 (2.2)</td></tr><tr><td colspan="2" rowspan="1">Concomitant drugs for HF and comorbidities, n (%)</td></tr><tr><td colspan="1" rowspan="1">&#8195;ACE inhibitor/ARB</td><td colspan="1" rowspan="1">116 (32.3)</td></tr><tr><td colspan="1" rowspan="1">&#8195;<italic toggle="yes">&#946;</italic>-blocker</td><td colspan="1" rowspan="1">218 (60.7)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Calcium-channel blocker</td><td colspan="1" rowspan="1">98 (27.3)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Statins</td><td colspan="1" rowspan="1">111 (30.9)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Diuretics</td><td colspan="1" rowspan="1">89 (24.8)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Antidiabetic drugs</td><td colspan="1" rowspan="1">40 (11.1)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Anticoagulant drugs</td><td colspan="1" rowspan="1">286 (79.7)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ACE</italic> Angiotensin converting enzyme, <italic toggle="yes">ARB</italic> Angiotensin II receptor blocker, <italic toggle="yes">Ccr</italic> Creatinine clearance, <italic toggle="yes">C/D</italic> Concentration-to-dose, <italic toggle="yes">HFmrEF</italic> Heart failure with mid-range ejection fraction; <italic toggle="yes">HFpEF</italic> Heart failure with preserved ejection fraction, <italic toggle="yes">HFrEF</italic> Heart failure with reduced ejection fraction, <italic toggle="yes">LVEF</italic> Left ventricular ejection fraction</p><p><sup>a</sup>LVEF&lt;&#8201;40%</p><p><sup>b</sup>40%&#8806;LVEF&lt;&#8201;50%</p><p><sup>C</sup>50%&#8806;LVEF</p><p><sup>d</sup>Each value represents the median (25 to 75% percentile)</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patients</title><p id="Par17">In total, 359 patients with HF who received oral bepridil were eligible for analysis (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The characteristics of the patients are listed in Table <xref rid="Tab1" ref-type="table">1</xref>. A total of 359 patients [238 men, 121 women; median age: 71&#8201;years (range: 64&#8211;79&#8201;years); body mass index: 23.41&#8201;kg/m<sup>2</sup> (range: 21.15&#8211;25.65&#8201;kg/m<sup>2</sup>)] were included. The median dose of bepridil was 1.58&#8201;mg/day/kg, and the median treatment period was nearly 1 year. Approximately 90% of the patients were diagnosed with HF with preserved ejection fraction, and less than 5% had HF with reduced ejection fraction. The patients with HF enrolled in this study had AF as a comorbidity. The value of serum albumin could not be investigated since there were many cases with missing data about serum albumin levels (65%, <italic toggle="yes">n</italic>&#8201;=&#8201;235/359).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart for the selection of included patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40780_2023_278_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Relationship between bepridil dose and plasma bepridil concentration</title><p id="Par18">A significant moderate correlation was observed between the bepridil dose and its plasma concentration (<italic toggle="yes">r</italic>&#8201;=&#8201;0.503, <italic toggle="yes">p</italic>&#8201;&lt;0.001) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). A significant correlation was observed between the bepridil dose and its plasma concentration in the non-polypharmacy group (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A), whereas no correlation was observed in the polypharmacy group (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Correlation between plasma bepridil concentration and its daily dose in patients with HF</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40780_2023_278_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Correlation between bepridil daily dose and plasma concentration under non-polypharmacy and polypharmacy in patients with HF. <bold>A</bold> Non-polypharmacy (<bold>B</bold>) Polypharmacy</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="40780_2023_278_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Factors contributing to plasma bepridil concentrations &#8805;800&#8201;ng/mL</title><p id="Par19">Univariate analysis revealed that age (<italic toggle="yes">p</italic>&#8201;=&#8201;0.019), daily dose of bepridil (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), serum creatinine (<italic toggle="yes">p</italic>&#8201;=&#8201;0.027), Ccr (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002), number of concomitant drugs (<italic toggle="yes">p</italic>&#8201;&lt;0.001), LVEF (<italic toggle="yes">p</italic>&#8201;=&#8201;0.029), and concomitant use of aprindine (<italic toggle="yes">p</italic>&#8201;=&#8201;0.023) all contributed to plasma bepridil concentrations reaching &#8805;800&#8201;ng/mL in patients (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Multivariate logistic regression analysis revealed that the adjusted odds ratios for a daily dose of bepridil &#8805;1.6&#8201;mg/kg, polypharmacy, and concomitant of aprindine were 6.82 (95% coefficient interval: 2.104&#8211;22.132, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001), 2.96 (95% coefficient interval: 1.014&#8211;8.643, <italic toggle="yes">p</italic>&#8201;=&#8201;0.047), and 8.63 (95% coefficient interval: 1.684&#8211;44.215, <italic toggle="yes">p</italic>&#8201;=&#8201;0.010), respectively (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The Hosmer&#8211;Lemeshow test determined the <italic toggle="yes">p</italic>-value for the goodness of fit of the multivariate logistic regression to be 0.366, and the accuracy rate of the regression was 93.9%. The VIF values for age, daily bepridil dose, Ccr, LVEF, and number of concomitant drugs were 2.339, 1.042, 2.416, 1.063, and 1.204, respectively.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Univariate analysis of factors contributing to plasma bepridil concentration in patients with HF</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Factors</th><th colspan="1" rowspan="1">&lt;800&#8201;ng/mL</th><th colspan="1" rowspan="1">&#8805;800&#8201;ng/mL</th><th rowspan="2" colspan="1"><italic toggle="yes">p</italic> value</th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;335</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;24</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sex (Male/Female)</td><td colspan="1" rowspan="1">223/112</td><td colspan="1" rowspan="1">15/9</td><td colspan="1" rowspan="1">0.684<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1">70.33&#8201;&#177;&#8201;10.89<sup>d</sup></td><td colspan="1" rowspan="1">75.08&#8201;&#177;&#8201;10.51<sup>d</sup></td><td colspan="1" rowspan="1">0.019<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Height (m)</td><td colspan="1" rowspan="1">1.63&#8201;&#177;&#8201;0.10<sup>d</sup></td><td colspan="1" rowspan="1">1.59&#8201;&#177;&#8201;0.11<sup>d</sup></td><td colspan="1" rowspan="1">0.058<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Body weight (kg)</td><td colspan="1" rowspan="1">63.45&#8201;&#177;&#8201;13.81<sup>d</sup></td><td colspan="1" rowspan="1">58.21&#8201;&#177;&#8201;12.17<sup>d</sup></td><td colspan="1" rowspan="1">0.079<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1">23.63&#8201;&#177;&#8201;3.79<sup>d</sup></td><td colspan="1" rowspan="1">22.98&#8201;&#177;&#8201;3.87<sup>d</sup></td><td colspan="1" rowspan="1">0.570<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Daily dose of bepridil (mg/kg body weight)</td><td colspan="1" rowspan="1">1.61&#8201;&#177;&#8201;0.59<sup>d</sup></td><td colspan="1" rowspan="1">2.18&#8201;&#177;&#8201;0.69<sup>d</sup></td><td colspan="1" rowspan="1">&lt;0.001<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Serum creatinine (mg/dL)</td><td colspan="1" rowspan="1">0.93&#8201;&#177;&#8201;0.41<sup>d</sup></td><td colspan="1" rowspan="1">1.12&#8201;&#177;&#8201;0.47<sup>d</sup></td><td colspan="1" rowspan="1">0.027<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Ccr (mL/min)</td><td colspan="1" rowspan="1">69.68&#8201;&#177;&#8201;29.43<sup>d</sup></td><td colspan="1" rowspan="1">52.12&#8201;&#177;&#8201;28.43<sup>d</sup></td><td colspan="1" rowspan="1">0.002<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">LVEF (%)</td><td colspan="1" rowspan="1">63.51&#8201;&#177;&#8201;10.65<sup>d</sup></td><td colspan="1" rowspan="1">59.52&#8201;&#177;&#8201;10.23<sup>d</sup></td><td colspan="1" rowspan="1">0.029<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1">Number of concomitant drugs</td><td colspan="1" rowspan="1">4.70&#8201;&#177;&#8201;3.51<sup>d</sup></td><td colspan="1" rowspan="1">8.17&#8201;&#177;&#8201;3.87<sup>d</sup></td><td colspan="1" rowspan="1">&lt;0.001<sup>c</sup></td></tr><tr><td colspan="4" rowspan="1">Properties of concomitant drugs</td></tr><tr><td colspan="4" rowspan="1">&#8195;Typical inducer of CYP enzymes</td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Carbamazepine, n (%)</td><td colspan="1" rowspan="1">1 (0.30)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">1.000<sup>b</sup></td></tr><tr><td colspan="4" rowspan="1">&#8195;Typical inhibitor of CYP enzymes</td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Clarithromycin, n (%)</td><td colspan="1" rowspan="1">1 (0.30)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">1.000<sup>b</sup></td></tr><tr><td colspan="4" rowspan="1">&#8195;CYP2D6 inhibitor</td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Aprindine, n (%)</td><td colspan="1" rowspan="1">7 (2.1)</td><td colspan="1" rowspan="1">3 (14.3)</td><td colspan="1" rowspan="1">0.023<sup>b</sup></td></tr><tr><td colspan="4" rowspan="1">&#8195;Typical inhibitor of P-gp</td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Verapamil</td><td colspan="1" rowspan="1">4 (1.2)</td><td colspan="1" rowspan="1">1 (4.3)</td><td colspan="1" rowspan="1">0.294<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Digoxin</td><td colspan="1" rowspan="1">4 (1.2)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">1.000<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Amiodarone</td><td colspan="1" rowspan="1">3 (0.9)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">1.000<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Diltiazem</td><td colspan="1" rowspan="1">6 (1.8)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">1.000<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#8195;&#8195;Nifedipine</td><td colspan="1" rowspan="1">5 (1.5)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">1.000<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Ccr</italic> Creatinine clearance, <italic toggle="yes">CYP</italic> Cytochrome P450, <italic toggle="yes">P-gp</italic> P-glycoprotein, <italic toggle="yes">LVEF</italic> Left ventricular ejection fraction</p><p><sup>a</sup>Chi-square test. <sup>b</sup>Fisher&#8217;s exact test. <sup>c</sup>Mann&#8211;Whitney U test. <sup>d</sup>Each value represents the mean&#8201;&#177;&#8201;standard deviation</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Factors influencing the plasma bepridil concentration&#8201;&#8805;800&#8201;ng/mL in patients with HF on multivariate logistic analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Factors</th><th colspan="1" rowspan="1">Adjusted OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age&#8201;&#8805;70&#8201;years</td><td colspan="1" rowspan="1">1.90</td><td colspan="1" rowspan="1">0.571&#8211;6.321</td><td colspan="1" rowspan="1">0.295</td></tr><tr><td colspan="1" rowspan="1">Daily dose of bepridil &#8805;1.6&#8201;mg/kg body weight</td><td colspan="1" rowspan="1">6.82</td><td colspan="1" rowspan="1">2.104&#8211;22.132</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Polypharmacy</td><td colspan="1" rowspan="1">2.96</td><td colspan="1" rowspan="1">1.014&#8211;8.643</td><td colspan="1" rowspan="1">0.047</td></tr><tr><td colspan="1" rowspan="1">Concomitant of aprindine</td><td colspan="1" rowspan="1">8.63</td><td colspan="1" rowspan="1">1.684&#8211;44.215</td><td colspan="1" rowspan="1">0.010</td></tr><tr><td colspan="1" rowspan="1">Ccr&#8201;&#8804;30&#8201;mL/min</td><td colspan="1" rowspan="1">2.75</td><td colspan="1" rowspan="1">0.848&#8211;8.927</td><td colspan="1" rowspan="1">0.092</td></tr><tr><td colspan="1" rowspan="1">LVEF &#8804;50%</td><td colspan="1" rowspan="1">1.76</td><td colspan="1" rowspan="1">0.578&#8211;5.358</td><td colspan="1" rowspan="1">0.320</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Ccr</italic> Creatinine clearance, <italic toggle="yes">LVEF</italic> Left ventricular ejection fraction, <italic toggle="yes">OR</italic> Odds ratio, <italic toggle="yes">95% CI</italic> 95% coefficient interval</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Association between polypharmacy and plasma bepridil concentration</title><p id="Par20">Although the C/D ratios in the groups receiving 6&#8211;9 and&#8201;10&#8804; drugs were 1.28- and 1.70-fold higher than that in the group receiving &lt;&#8201;6 drugs, respectively, no significant difference was observed in C/D ratios between the groups receiving 6&#8211;9 and&#8201;10&#8804; drugs (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Correlation of the number of concomitant drugs used with the C/D ratio of bepridil in patients with HF. Each column represents the mean&#8201;&#177;&#8201;standard deviation. **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 and ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 compared with the number of concomitant drugs &lt;&#8201;6. NS, not significant; C/D, concentration-to-dose ratio</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="40780_2023_278_Fig4_HTML.jpg"/></fig></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par21">As the condition of HF worsens, the number of concomitant drugs required to control the disease rises [<xref ref-type="bibr" rid="CR8">8</xref>], resulting in drug interactions and may affect the pharmacological effect of bepridil. Therefore, it is necessary to examine the effect of the increase in the number of concomitant drugs on plasma bepridil concentrations. To the best of our knowledge, this is the first study to demonstrate that polypharmacy may increase the plasma bepridil concentration in patients with HF.</p><p id="Par22">Although the rate of AF conversion to sinus rhythm is associated with a linear dose-response relationship of bepridil [<xref ref-type="bibr" rid="CR21">21</xref>], excessive plasma bepridil concentration causes QT prolongation and torsades de pointes. A meta-analysis revealed that QT prolongation is associated with cardiovascular and sudden death [<xref ref-type="bibr" rid="CR22">22</xref>], suggesting that patients with HF should be carefully monitored. Several studies reported that plasma bepridil concentration correlates with the daily dose [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], and this phenomenon is consistent with the findings of the present study (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). However, excessively high plasma concentrations of bepridil were observed in a few cases. Metabolic saturation of bepridil mediated by CYP2D6 was observed; the <italic toggle="yes">CYP2D6*10</italic> allele may reduce oral clearance [<xref ref-type="bibr" rid="CR12">12</xref>]. Moreover, patients with HF experience major fluctuations in systemic circulation and organ perfusion as HF progresses [<xref ref-type="bibr" rid="CR23">23</xref>], suggesting that intra-individual variability in the pharmacokinetics of bepridil may be more significant in patients with HF than that in other patients. Therefore, it was considered necessary to conduct a population pharmacokinetic analysis to take into account intra- and inter-individual variability in plasma bepridil concentration in HF patients for further investigation.</p><p id="Par23">The excretion rate of unchanged bepridil in urine is &lt;&#8201;0.1%, and dose adjustment is not considered essential in end-stage renal disease [<xref ref-type="bibr" rid="CR24">24</xref>]. Therefore, a decrease in Ccr is unlikely to induce plasma bepridil concentrations &#8805;800&#8201;ng/mL. Shimamoto et al. reported that the clearance of vancomycin, a typical drug excreted into the urine, is affected by LVEF reduction in congestive HF [<xref ref-type="bibr" rid="CR25">25</xref>]. As a mechanism for this alteration, they speculated that the renal blood flow reduces owing to decreased cardiac output. Thus, the lack of any effect of LVEF &#8804;50% on plasma bepridil concentration could be attributed to its excretion pathway. Decreased cardiac output also significantly reduces hepatic blood flow in patients with HF [<xref ref-type="bibr" rid="CR23">23</xref>]. Furthermore, an animal study revealed that HF-induced hepatic ischemia reduces the clearance of propranolol, a substrate of CYP2D [<xref ref-type="bibr" rid="CR26">26</xref>], suggesting that the decline in hepatic blood flow mediated by LVEF decrease may require further examination for alterations in the CYP2D6-induced metabolic activity of bepridil. However, as only 3.9% of the patients with HF enrolled in the present study had an LVEF of &lt;40% (Table <xref rid="Tab1" ref-type="table">1</xref>), the effect of LVEF attenuation on bepridil clearance was likely under-assessed.</p><p id="Par24">A previous study revealed that human serum albumin may have at least two bepridil binding sites [<xref ref-type="bibr" rid="CR27">27</xref>]. Although an in vitro study found that the free fraction of bepridil increased following the addition of verapamil, nifedipine, diltiazem, disopyramide, or warfarin to a patient&#8217;s treatment regimen, these added concentrations were much higher than the clinical blood concentration [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, it is unlikely that competitive inhibition of serum albumin binding between bepridil and other drugs would occur in clinical settings. Although the serum albumin levels of enrolled patients were not available, the concomitant rates of verapamil, nifedipine, and diltiazem were not significantly different between the &#8805;800&#8201;ng/mL and&#8201;&lt;800&#8201;ng/mL serum concentration groups (Table <xref rid="Tab2" ref-type="table">2</xref>), suggesting that variations in the protein binding rate of bepridil have a very low impact on the results of this study.</p><p id="Par25">Concomitant use of aprindine, a competitive inhibitor of CYP2D6, maintains the dose&#8211;blood concentration correlation; however, it increases its slope compared to that without aprindine. The concomitant use of aprindine was also shown in this study to be a risk factor for increasing plasma levels of bepridil (Table <xref rid="Tab3" ref-type="table">3</xref>). CYP2D6 inhibition was considered one of the mechanisms affecting plasma concentrations of bepridil, and a correlation analysis was performed between dose and plasma concentration under polypharmacy status. However, while a moderate correlation for non-polypharmacy was observed (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A), a correlation was not observed for polypharmacy (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B). Bepridil is a substrate of P-gp, an efflux transporter, and its absorption in the small intestine may be affected [<xref ref-type="bibr" rid="CR13">13</xref>]. Although typical inhibitors of P-gp would not affect plasma bepridil concentration in our results (Table <xref rid="Tab2" ref-type="table">2</xref>), it was possible that the P-gp inhibitory effect could not be fully evaluated due to the very small number of patients taking these drugs. Therefore, it was speculated that polypharmacy could have influenced the absorption, metabolism, or other pathways associated with the pharmacokinetics of bepridil; however, the details remain unknown. HF progression is slow; the number of therapeutic drugs used increases with comorbidities [<xref ref-type="bibr" rid="CR28">28</xref>]. The C/D ratio increases in correlation with an increase in the number of concomitant drugs used (Fig. <xref rid="Fig4" ref-type="fig">4</xref>), indicating that there may be a risk of dose-independent increases in the plasma concentration of bepridil as HF progresses.</p><p id="Par26">In the multivariate logistic regression model, the number size corresponding to bepridil concentrations &#8805;800&#8201;ng/mL group was 24, which likely resulted in overfitting owing to 6 explanatory variables. However, the <italic toggle="yes">p</italic> value obtained in the Hosmer&#8211;Lemeshow test was 0.366, and the accuracy was 93.9%, suggesting that this model may show acceptable fit. In addition, the low VIF value suggested the absence of multicollinearity.</p><p id="Par27">Our study had several limitations. First, the blood collection time included non-trough sampling. However, steady-state plasma bepridil concentration did not differ between 2 and 10&#8201;h after bepridil treatment [<xref ref-type="bibr" rid="CR29">29</xref>] owing to its long half-life (48&#8211;80&#8201;h), suggesting that the time of blood collection had a minor effect on plasma bepridil concentrations. Second, because this study design was a retrospective observation, the effect of the edema, ascites, and urine volume on plasma bepridil concentrations could not be evaluated. Third, the inclusion of patients with poor adherence to bepridil would result in underestimating the plasma drug levels. Considering these limitations, further prospective studies are needed to be conducted. Nonetheless, the vital aspects of this study remain that it was a multicenter experiment with enough eligible patients with HF and minimal enough bias to allow for scientific rigor and external validity.</p></sec><sec id="Sec13"><title>Conclusions</title><p id="Par28">Plasma concentrations of bepridil may be influenced by polypharmacy. Because the plasma bepridil concentration further increased in correlation with the number of concomitant drugs used, periodic monitoring of plasma bepridil concentration should be performed to facilitate safe use in patients with HF.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>We thank Takumi Tashiro, Hiroya Muro, Arisa Bino, Ryohei Suzuki, and Yuji Hayakawa for institutional enrollment and data collection in this study. We would like to thank Editage (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.editage.com">www.editage.com</ext-link>) for English language editing.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Conceived of designed the study: Yuki Asai and Yoshiaki Yamamoto.</p><p>Performed research: Yuki Asai, Hiroki Arihara, Saki Omote, Ena Tanio, Saena Yamashita, Takashi Higuchi, Ei Hashimoto, Momoko Yamada, Hinako Tsuji, Yoshihiro Kondo, Makoto Hayashi, and Yoshiaki Yamamoto.</p><p>Analyzed data: Yuki Asai, Hiroki Arihara, Saki Omote, Ena Tanio, Saena Yamashita, Takashi Higuchi, Ei Hashimoto, Momoko Yamada, Hinako Tsuji, Yoshihiro Kondo, Makoto Hayashi, and Yoshiaki Yamamoto.</p><p>Wrote the paper: Yuki Asai.&#160;The author(s) read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The present study was funded by grants from the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) (grant no. 22&#8201;K15331).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data supporting the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par29">This study was performed in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study protocol was approved by the ethics committee of Kanazawa Medical Center (approval ref. R03&#8211;069), Mie Chuo Medical Center (approval ref. MCERB-202129), and Nagoya Medical Center (approval ref. 2021&#8211;053). Owing to the retrospective case-control study design, consent was obtained from each patient using an opt-out document posted on the websites of the respective hospitals.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par30">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par31">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>A</given-names></name><name name-style="western"><surname>Flaim</surname><given-names>SF</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>BP</given-names></name><name name-style="western"><surname>Sit</surname><given-names>SP</given-names></name><name name-style="western"><surname>Brannan</surname><given-names>MD</given-names></name></person-group><article-title>Pharmacology of bepridil</article-title><source>Am J Cardiol</source><year>2019</year><volume>69</volume><fpage>11D</fpage><lpage>16D</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(92)90953-V</pub-id><pub-id pub-id-type="pmid">1372785</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>M</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Wakeyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Iwami</surname><given-names>T</given-names></name><name name-style="western"><surname>Hadano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>A</given-names></name><name name-style="western"><surname>Matsuzaki</surname><given-names>M</given-names></name></person-group><article-title>Cardioversion of amiodarone-insensitive atrial fibrillation by bepridil in heart failure: two case reports</article-title><source>J Cardiol</source><year>2006</year><volume>48</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">17243631</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiga</surname><given-names>T</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name><name name-style="western"><surname>Naganuma</surname><given-names>M</given-names></name><name name-style="western"><surname>Hosaka</surname><given-names>F</given-names></name><name name-style="western"><surname>Shoda</surname><given-names>M</given-names></name><name name-style="western"><surname>Hagiwara</surname><given-names>N</given-names></name></person-group><article-title>Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil</article-title><source>Circ J</source><year>2011</year><volume>75</volume><fpage>1334</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-10-1084</pub-id><pub-id pub-id-type="pmid">21483159</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yakabe</surname><given-names>D</given-names></name><name name-style="western"><surname>Aso</surname><given-names>A</given-names></name><name name-style="western"><surname>Araki</surname><given-names>M</given-names></name><name name-style="western"><surname>Murasato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Efficacy of hybrid therapy using prior administration of bepridil hydrochloride and cryoballoon ablation in patients with persistent atrial fibrillation</article-title><source>J Cardiol</source><year>2020</year><volume>75</volume><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2019.08.017</pub-id><pub-id pub-id-type="pmid">31540839</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsui</surname><given-names>K</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sakakura</surname><given-names>K</given-names></name><name name-style="western"><surname>Wada</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relationship between serum bepridil concentration and corrected QT interval</article-title><source>Int J Clin Pharmacol Ther.</source><year>2020</year><volume>59</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.5414/CP203843</pub-id><pub-id pub-id-type="pmid">33026317</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name></person-group><article-title>Pharmacokinetics and metabolism of bepridil</article-title><source>Am J Cardiol</source><year>1985</year><volume>55</volume><fpage>8C</fpage><lpage>13C</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(85)90799-4</pub-id><pub-id pub-id-type="pmid">3872057</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woosley</surname><given-names>RL</given-names></name><name name-style="western"><surname>Echt</surname><given-names>DS</given-names></name><name name-style="western"><surname>Roden</surname><given-names>DM</given-names></name></person-group><article-title>Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents</article-title><source>Am J Cardiol</source><year>1986</year><volume>57</volume><fpage>25B</fpage><lpage>33B</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(86)90995-1</pub-id><pub-id pub-id-type="pmid">3080860</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beezer</surname><given-names>J</given-names></name><name name-style="western"><surname>Al Hatrushi</surname><given-names>M</given-names></name><name name-style="western"><surname>Husband</surname><given-names>A</given-names></name><name name-style="western"><surname>Kurdi</surname><given-names>A</given-names></name><name name-style="western"><surname>Forsyth</surname><given-names>P</given-names></name></person-group><article-title>Polypharmacy definition and prevalence in heart failure: a systematic review</article-title><source>Heart Fail Rev</source><year>2022</year><volume>27</volume><fpage>465</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1007/s10741-021-10135-4</pub-id><pub-id pub-id-type="pmid">34213753</pub-id><pub-id pub-id-type="pmcid">PMC8250543</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kojima</surname><given-names>T</given-names></name><name name-style="western"><surname>Akishita</surname><given-names>M</given-names></name><name name-style="western"><surname>Kameyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Eto</surname><given-names>M</given-names></name><name name-style="western"><surname>Ouchi</surname><given-names>Y</given-names></name></person-group><article-title>High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database</article-title><source>Geriatr Gerontol Int</source><year>2012</year><volume>12</volume><fpage>761</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1111/j.1447-0594.2012.00868.x</pub-id><pub-id pub-id-type="pmid">22998384</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kojima</surname><given-names>T</given-names></name><name name-style="western"><surname>Akishita</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>K</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Iijima</surname><given-names>K</given-names></name><name name-style="western"><surname>Eto</surname><given-names>M</given-names></name><name name-style="western"><surname>Ouchi</surname><given-names>Y</given-names></name></person-group><article-title>Polypharmacy as a risk for fall occurrence in geriatric outpatients</article-title><source>Geriatr Gerontol Int</source><year>2012</year><volume>12</volume><fpage>425</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1111/j.1447-0594.2011.00783.x</pub-id><pub-id pub-id-type="pmid">22212467</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Georgiev</surname><given-names>KD</given-names></name><name name-style="western"><surname>Hvarchanova</surname><given-names>N</given-names></name><name name-style="western"><surname>Georgieva</surname><given-names>M</given-names></name><name name-style="western"><surname>Kanazirev</surname><given-names>B</given-names></name></person-group><article-title>The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients</article-title><source>Int J Clin Pharm</source><year>2019</year><volume>41</volume><fpage>1555</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.1007/s11096-019-00918-z</pub-id><pub-id pub-id-type="pmid">31595450</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujiki</surname><given-names>A</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>J</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>K</given-names></name><name name-style="western"><surname>Saigusa</surname><given-names>K</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>I</given-names></name><name name-style="western"><surname>Oshima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>Y</given-names></name></person-group><article-title>Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias</article-title><source>Biol Pharm Bull</source><year>2006</year><volume>29</volume><fpage>517</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1248/bpb.29.517</pub-id><pub-id pub-id-type="pmid">16508157</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safa</surname><given-names>AR</given-names></name></person-group><article-title>Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil</article-title><source>Proc Natl Acad Sci U S A</source><year>1988</year><volume>85</volume><fpage>7187</fpage><lpage>7191</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.19.7187</pub-id><pub-id pub-id-type="pmid">2902625</pub-id><pub-id pub-id-type="pmcid">PMC282149</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miura</surname><given-names>S</given-names></name><name name-style="western"><surname>Sumiyoshi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>H</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Seigen</surname><given-names>I</given-names></name><name name-style="western"><surname>Okai</surname><given-names>I</given-names></name><name name-style="western"><surname>Masaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Komatsu</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Sekita</surname><given-names>G</given-names></name><name name-style="western"><surname>Tokano</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakazato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Daida</surname><given-names>H</given-names></name></person-group><article-title>The use of serum bepridil concentration as a safe rhythm control strategy in patients with atrial tachyarrhythmias</article-title><source>J Arrhy</source><year>2012</year><volume>28</volume><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.joa.2012.02.015</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Turpeinen</surname><given-names>M</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name></person-group><article-title>Inhibition and induction of CYP enzymes in humans: an update</article-title><source>Arch Toxicol</source><year>2020</year><volume>94</volume><fpage>3671</fpage><lpage>3722</lpage><pub-id pub-id-type="doi">10.1007/s00204-020-02936-7</pub-id><pub-id pub-id-type="pmid">33111191</pub-id><pub-id pub-id-type="pmcid">PMC7603454</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagodinsky</surname><given-names>JC</given-names></name><name name-style="western"><surname>Akgun</surname><given-names>U</given-names></name></person-group><article-title>Characterizing the binding interactions between P-glycoprotein and eight known cardiovascular transport substrates</article-title><source>Pharmacol Res Perspect</source><year>2015</year><volume>3</volume><fpage>e00114</fpage><pub-id pub-id-type="doi">10.1002/prp2.114</pub-id><pub-id pub-id-type="pmid">25729581</pub-id><pub-id pub-id-type="pmcid">PMC4324688</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fricker</surname><given-names>G</given-names></name><name name-style="western"><surname>Drewe</surname><given-names>J</given-names></name><name name-style="western"><surname>Huwyler</surname><given-names>J</given-names></name><name name-style="western"><surname>Gutmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Beglinger</surname><given-names>C</given-names></name></person-group><article-title>Relevance of p-glycoprotein for the enteral absorption of cyclosporin a: in vitro-in vivo correlation</article-title><source>Br J Pharmacol</source><year>1996</year><volume>118</volume><fpage>1841</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1996.tb15612.x</pub-id><pub-id pub-id-type="pmid">8842452</pub-id><pub-id pub-id-type="pmcid">PMC1909843</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Floren</surname><given-names>LC</given-names></name><name name-style="western"><surname>Bekersky</surname><given-names>I</given-names></name><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Mekki</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dressler</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hebert</surname><given-names>MF</given-names></name></person-group><article-title>Tacrolimus oral bioavailability doubles with coadministration of ketoconazole</article-title><source>Clin Pharmacol Ther</source><year>1997</year><volume>62</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S0009-9236(97)90150-8</pub-id><pub-id pub-id-type="pmid">9246018</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cockcroft</surname><given-names>DW</given-names></name><name name-style="western"><surname>Gault</surname><given-names>MH</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000180580</pub-id><pub-id pub-id-type="pmid">1244564</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiga</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashiguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Naganuma</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name><name name-style="western"><surname>Hagiwara</surname><given-names>N</given-names></name></person-group><article-title>Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics</article-title><source>Ther Drug Monit</source><year>2013</year><volume>35</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e318286ec33</pub-id><pub-id pub-id-type="pmid">23666576</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T</given-names></name><name name-style="western"><surname>Aizawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Atarashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujiki</surname><given-names>A</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H</given-names></name><name name-style="western"><surname>Ito</surname><given-names>M</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>T</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Koretsune</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>K</given-names></name><name name-style="western"><surname>Niwano</surname><given-names>S</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>O</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>K</given-names></name><name name-style="western"><surname>Saku</surname><given-names>K</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>T</given-names></name><name name-style="western"><surname>Origasa</surname><given-names>H</given-names></name><name name-style="western"><surname>Investigators</surname><given-names>J-BAF</given-names></name></person-group><article-title>Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study)</article-title><source>Circ J</source><year>2009</year><volume>73</volume><fpage>1020</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-08-1061</pub-id><pub-id pub-id-type="pmid">19359813</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Post</surname><given-names>WS</given-names></name><name name-style="western"><surname>Blasco-Colmenares</surname><given-names>E</given-names></name><name name-style="western"><surname>Dalal</surname><given-names>D</given-names></name><name name-style="western"><surname>Tomaselli</surname><given-names>GF</given-names></name><name name-style="western"><surname>Guallar</surname><given-names>E</given-names></name></person-group><article-title>Electrocardiographic QT interval and mortality: a meta-analysis</article-title><source>Epidemiology</source><year>2011</year><volume>22</volume><fpage>660</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1097/EDE.0b013e318225768b</pub-id><pub-id pub-id-type="pmid">21709561</pub-id><pub-id pub-id-type="pmcid">PMC3150395</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leithe</surname><given-names>ME</given-names></name><name name-style="western"><surname>Margorien</surname><given-names>RD</given-names></name><name name-style="western"><surname>Hermiller</surname><given-names>JB</given-names></name><name name-style="western"><surname>Unverferth</surname><given-names>DV</given-names></name><name name-style="western"><surname>Leier</surname><given-names>CV</given-names></name></person-group><article-title>Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure</article-title><source>Circulation</source><year>1984</year><volume>69</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.69.1.57</pub-id><pub-id pub-id-type="pmid">6689647</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awni</surname><given-names>WM</given-names></name><name name-style="western"><surname>Halstenson</surname><given-names>CE</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>RK</given-names></name><name name-style="western"><surname>Opsahl</surname><given-names>JA</given-names></name><name name-style="western"><surname>Desiraju</surname><given-names>RK</given-names></name><name name-style="western"><surname>Minn</surname><given-names>FL</given-names></name><name name-style="western"><surname>Matzke</surname><given-names>GR</given-names></name></person-group><article-title>Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease</article-title><source>J Clin Pharmacol</source><year>1995</year><volume>35</volume><fpage>379</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1995.tb04077.x</pub-id><pub-id pub-id-type="pmid">7650227</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>T</given-names></name><name name-style="western"><surname>Tominari</surname><given-names>S</given-names></name><name name-style="western"><surname>Fukumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>K</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Shirasaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Komori</surname><given-names>K</given-names></name></person-group><article-title>Decreased vancomycin clearance in patients with congestive heart failure</article-title><source>Eur J Clin Pharmacol</source><year>2013</year><volume>69</volume><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1007/s00228-012-1340-4</pub-id><pub-id pub-id-type="pmid">22791272</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>CY</given-names></name><name name-style="western"><surname>Ghabrial</surname><given-names>H</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Ching</surname><given-names>MS</given-names></name><name name-style="western"><surname>Smallwood</surname><given-names>RA</given-names></name><name name-style="western"><surname>Angus</surname><given-names>PW</given-names></name></person-group><article-title>Impaired elimination of propranolol due to right heart failure: drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity</article-title><source>Drug Metab Dispos</source><year>2000</year><volume>28</volume><fpage>1217</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">10997943</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pritchard</surname><given-names>JF</given-names></name><name name-style="western"><surname>McKown</surname><given-names>LA</given-names></name><name name-style="western"><surname>Dvorchik</surname><given-names>BH</given-names></name><name name-style="western"><surname>O'Neill</surname><given-names>PJ</given-names></name></person-group><article-title>Plasma protein binding of bepridil</article-title><source>J Clin Pharmacol</source><year>1985</year><volume>25</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1985.tb02853.x</pub-id><pub-id pub-id-type="pmid">3875635</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unlu</surname><given-names>O</given-names></name><name name-style="western"><surname>Levitan</surname><given-names>EB</given-names></name><name name-style="western"><surname>Reshetnyak</surname><given-names>E</given-names></name><name name-style="western"><surname>Kneifati-Hayek</surname><given-names>J</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>I</given-names></name><name name-style="western"><surname>Archambault</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Hanlon</surname><given-names>JT</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>MS</given-names></name><name name-style="western"><surname>Safford</surname><given-names>MM</given-names></name><name name-style="western"><surname>Lachs</surname><given-names>MS</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>P</given-names></name></person-group><article-title>Polypharmacy in older adults hospitalized for heart failure</article-title><source>Circ Heart Fail</source><year>2020</year><volume>13</volume><fpage>e006977</fpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.120.006977</pub-id><pub-id pub-id-type="pmid">33045844</pub-id><pub-id pub-id-type="pmcid">PMC8819498</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kusano</surname><given-names>A</given-names></name><name name-style="western"><surname>Noro</surname><given-names>M</given-names></name><name name-style="western"><surname>Numata</surname><given-names>A</given-names></name><name name-style="western"><surname>Tezuka</surname><given-names>N</given-names></name><name name-style="western"><surname>Nakae</surname><given-names>T</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>T</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>K</given-names></name><name name-style="western"><surname>Monyama</surname><given-names>A</given-names></name><name name-style="western"><surname>Kujime</surname><given-names>S</given-names></name><name name-style="western"><surname>Asayama</surname><given-names>T</given-names></name></person-group><article-title>Characteristics of pharmacokinetics of bepridil</article-title><source>Jpn J Electrocardiol</source><year>2007</year><volume>27</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.5105/jse.27.30</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>